Drawing for BREYANZI

USPTO serial 88077381

BREYANZI

Reviewed by CopyMark Law Group

Reg. 5709663Status 702Registered
Filing date
Status date
Registration date
Mar 26, 2019
Examiner
SOBRAL, CHRISTINA
Law office
Historical data usage

What this means

Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with BREYANZI?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Marilyn F. Kelly

Marilyn F. Kelly Bristol-Myers Squibb CompanyPO BOX 4000Trademark Dept., Mailstop D.4243PRINCETON, NJ 08648

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of cancer [ and auto-immune diseases ] ; pharmaceutical preparations for the treatment of lymphoma; pharmaceutical preparations for inhibiting cytokine production; pharmaceutical preparations that modulate the immune system [ ; cells for medical or clinical use; diagnostic kits consisting primarily of cells for medical or clinical use ]ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 30, 2024NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Sep 30, 2024C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Sep 30, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Mar 27, 2024E815TEAS SECTION 8 & 15 RECEIVED—
Mar 26, 2024REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Dec 9, 2022CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Dec 9, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Dec 9, 2022EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Dec 9, 2022ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 9, 2022REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Dec 9, 2022COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Oct 30, 2019ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Mar 26, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jan 8, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 8, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 19, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 30, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 30, 2018DOCKASSIGNED TO EXAMINER—
Nov 28, 2018ALIEASSIGNED TO LIE—
Nov 20, 2018PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Aug 22, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 17, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance